1
9
↑1
↓0
—9
Evidence suggests Creatine haslittle to no effecton Safety.
9 studies (10 claims)
Moderate consensus
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| one-year low-dose creatine supplementation (1g/d) | No effect - remained unaltered | safety laboratory parameters | Human | older postmenopausal women | 1g/d | Effects of long-term low-dose dietary creatine supplementation in older women.cited 41× |
| most of the evaluated creatine forms | No effect - unlikely to pose safety concerns | safety | Human | — | 3 g per day (for general creatine intake). | Creatine and creatine forms intended for sports nutrition.cited 18× |
| creatine orotate | No effect - some safety concerns | safety | Human | — | 3 g per day (for general creatine intake). | Creatine and creatine forms intended for sports nutrition.cited 18× |
| Creatine monohydrate | No effect - unlikely to pose safety concerns | safety | Human | healthy adults with exclusion of pregnant and breastfeeding women | 3 g per day (for general creatine intake). | Creatine and creatine forms intended for sports nutrition.cited 18× |
| magnesium creatine chelate | No effect - some safety concerns | safety | Human | — | 3 g per day (for general creatine intake). | Creatine and creatine forms intended for sports nutrition.cited 18× |
| creatine phosphate | No effect - some safety concerns | safety | Human | — | 3 g per day (for general creatine intake). | Creatine and creatine forms intended for sports nutrition.cited 18× |
| Q-ter 320 mg + creatine 340 mg | No effect - No untoward effects occurred | safety | Human | patients with stable CHF | Q-ter 320 mg + creatine 340 mg once daily. | Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study.cited 32× |
| creatine supplementation | No effect - is well tolerated and free of adverse effects | safety | Human | non-active C-SLE patients | 0.1 g/kg/day | Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial.cited 18× |
| creatine supplementation | Increases - is safe and well-tolerated | safety and tolerability | Human | children with JDM | Not specified in the abstract. | The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis: A Randomized, Double-blind, Placebo-controlled Feasibility Study.cited 10× |
| creatine | No effect - no safety concerns | safety | Human | Six participants with ALS | 5, 10, and 15 g twice daily (b.i.d.). | A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis.cited 28× |
| creatine | No effect - considered safe and without significant adverse effects | safety | Human | — | Variable, with multiple regimens showing benefits (specific amounts not detailed). | Creatine Use in Sports.cited 47× |
| creatine nitrate | No effect - there were no safety concerns | safety | Human | participants | 1.5 g CrN (CrN-Low), 3 g CrN (CrN-High), 5 g CrM (Study 1), 3 g CrM (Study 2) | Acute and chronic safety and efficacy of dose dependent creatine nitrate supplementation and exercise performance.cited 27× |
| creatine in addition to cognitive-behavioural therapy (CBT) | No effect - proportion of participants with at least one adverse event were comparable | safety (patients experiencing one or more adverse events) | Human | participants with depression | Not specified | Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area.cited 4× |